Navigation Links
A Novel, Quantitative Immunohistochemistry Method Enabled by BioGenex IHC System
Date:2/17/2017

FREMONT, Calif., Feb. 17, 2017 /PRNewswire/ -- BioGenex, a global leader in molecular pathology, is pleased to announce development of a novel system for quantitative immunohistochemistry (IHC). The system was developed in collaboration with the University of Rochester (NY, USA) and Konica-Minolta Inc. (Tokyo, Japan). The new system is able to accurately quantify the expression of an important breast cancer biomarker, HER2 (Human epidermal growth factor receptor-2) in clinical samples. Quantitative IHC is achieved by combining BioGenex IHC system with Konica-Minolta PID nanoparticles detection system (1). According to the study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS), the new method is more accurate and shows a broader dynamic range of values when compared with IHC quantitation. When compared to FISH analysis, PID score/cell showed a much better correlation (R2=0.72) as compared to standard IHC (R2=0.41). Moreover, by using BioGenex Xmatrx-Infinity workstation, quantitative IHC can be fully automated with high precision, as demonstrated by Standard deviation (SD) values below 12%. This novel method offers great potential for the quantitative measurement of biomarkers to advance precession medicine for cancer and possible other diseases using tissue and cytology specimen. Further development work is required to bring this technology to molecular pathology laboratory for clinical application. The study results are available for download here.

"Once again we demonstrate our ability to deliver cutting edge technology to solve unmet medical needs years ahead of our competition," said Dr. Krish Kalra, founder and CEO of BioGenex.

HER2 Quantitation in Clinical Breast Cancer Samples
HER2 Quantitation in Clinical Breast Cancer Samples
Correlation between PID score/cell and Antibody-Binding Capacity in 8 breast cancer cell lines by FACS analysis (R2=0.94)
Correlation between PID score/cell and Antibody-Binding Capacity in 8 breast cancer cell lines by FACS analysis (R2=0.94)

HER2 overexpression in breast cancer is associated with an aggressive clinical course and poor outcome and was the first predictive IHC biomarker approved by the FDA (licensed in 1998). Targeting HER2 overexpression is a remarkably effective therapeutic modality (e.g. trastuzumab/Herceptin), however, inaccuracy of current HER2 testing methods can lead to non-optimal therapy with an estimated economic loss of about $1 billion annually.

About BioGenex: BioGenex designs, develops and commercializes molecular pathology systems for cancer diagnosis, prognosis, precession medicine and life science research. The recent introduction of our cytogenetic FISH workflow solution and miRNA system for characterization of Cancer of Unknown Primary (CUP) and undifferentiated tumors are a game changer and envy of the industry. Our fully-automated molecular pathology workstations are the most advanced system available globally. BioGenex prides itself on delivering cutting edge technology, years ahead of its competition, providing the finest systems for immunohistochemistry (IHC), In Situ hybridization (ISH), FISH, Special stains and in situ PCR. BioGenex unconditionally guarantees performance of its systems and products: antibodies, probes, antigen retrieval, detection systems and histology stains. We are committed to provide quality systems and best in class customer care.

www.biogenex.com

Corporate Communication
Krishan Kalra, PhD, BioGenex Founder and CEO
800-421-4149
146629@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/a-novel-quantitative-immunohistochemistry-method-enabled-by-biogenex-ihc-system-300409127.html


'/>"/>
SOURCE BioGenex
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Alexi Venice’s Newly Released Second Novel, ‘SVEA’S SINS,’ is a Thriller About a 2018 Terrorist Plot Against the U.S. With Drones.
2. Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer
3. Lycera Announces Research Showing Novel, Oral Immunotherapy Possesses Potent Single Agent Anti-Cancer Activity
4. University of Illinois researchers demonstrate novel, tunable nanoantennas
5. Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology
6. Shimadzu’s New High-Sensitivity GCMS Offers Outstanding Qualitative/Quantitative Performance and Exceptional Reliability
7. Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1
8. New ROSA® WET®-S5 Aflatoxin Quantitative Test Receives USDA-GIPSA Approval
9. Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
10. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
11. Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue Using Myriad RBM’s Multiplex ApoptosisMAP™, a New Biomarker Webinar by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2018)... ... October 04, 2018 , ... ... identity and website that elevates the company’s brand identity and better reflects its ... offers a broader range of engineering expertise and related support services to clients ...
(Date:10/2/2018)... ... October 02, 2018 , ... ... endangers the reliability and reproducibility of experimental data. Each lab must consider whether ... educational webinar, which is sponsored by Eppendorf , attendees will learn how ...
(Date:9/28/2018)... , ... September 28, 2018 , ... ... events for tech innovators, engineers, and scientists from around the world, is excited ... National University of San Marcos, as the winner of the LabRoots Summer 2018 ...
(Date:9/27/2018)... , ... September 26, 2018 , ... ... biologics manufacturer, debuted its focus® Pedicle Screw System today at the North American ... 26-29. , The Nvision focus Pedicle Screw System, which received clearance ...
Breaking Biology Technology:
(Date:10/11/2018)... ... October 11, 2018 , ... Better lives through a healthy ... Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The Institute, a public-private partnership launched in March ... workforce development in the United States. Biopharmaceuticals are important because they treat and ...
(Date:10/5/2018)... ... October 04, 2018 , ... EDETEK, the premier provider of digital clinical trial ... in Bethesda, MD on October 8-12, 2018. EDETEK is also a Gold Sponsor of ... 2018. , CDISC Interchanges are global events held annually on three continents with ...
(Date:10/3/2018)... ... October 03, 2018 , ... ... on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced ... to patients with type 2 diabetes and progressive diabetic kidney disease in ...
Breaking Biology News(10 mins):